{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:53:06Z","timestamp":1790837586266,"version":"4.1.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41582-022-00634-9","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T06:03:00Z","timestamp":1648188180000},"page":"257-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Recessive cerebellar and afferent ataxias \u2014 clinical challenges and future directions"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8615-4390","authenticated-orcid":false,"given":"Marie","family":"Beaudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Manto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Schmahmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-6115","authenticated-orcid":false,"given":"Nicolas","family":"Dupre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"634_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMra2023935","volume":"383","author":"AA Amato","year":"2020","unstructured":"Amato, A. A. & Ropper, A. H. Sensory ganglionopathy. N. Engl. J. Med. 383, 1657\u20131662 (2020). A state-of-the-art review of acquired causes of sensory ganglionopathy.","journal-title":"N. Engl. J. Med."},{"key":"634_CR2","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/mds.27415","volume":"33","author":"M Rossi","year":"2018","unstructured":"Rossi, M. et al. The genetic nomenclature of recessive cerebellar ataxias. Mov. Disord. 33, 1056\u20131076 (2018). This article presents the revised nomenclature of recessive cerebellar ataxias, in which an ATX prefix is followed by the gene name.","journal-title":"Mov. Disord."},{"key":"634_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s12311-019-01052-2","volume":"18","author":"M Beaudin","year":"2019","unstructured":"Beaudin, M. et al. The classification of autosomal recessive cerebellar ataxias: a consensus statement from the society for research on the cerebellum and ataxias task force. Cerebellum 18, 1098\u20131125 (2019). A scoping systematic review of the literature on recessive cerebellar ataxias with a clinical classification and diagnostic approach.","journal-title":"Cerebellum"},{"key":"634_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358801","volume":"42","author":"L Ruano","year":"2014","unstructured":"Ruano, L., Melo, C., Silva, M. C. & Coutinho, P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 42, 174\u2013183 (2014).","journal-title":"Neuroepidemiology"},{"key":"634_CR5","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1073\/pnas.94.14.7452","volume":"94","author":"M Cossee","year":"1997","unstructured":"Cossee, M. et al. Evolution of the Friedreich\u2019s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc. Natl Acad. Sci. USA 94, 7452\u20137457 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","volume":"271","author":"V Campuzano","year":"1996","unstructured":"Campuzano, V. et al. Friedreich\u2019s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271, 1423\u20131427 (1996).","journal-title":"Science"},{"key":"634_CR7","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/ana.20333","volume":"56","author":"R Sharma","year":"2004","unstructured":"Sharma, R. et al. Friedreich ataxia in carriers of unstable borderline GAA triplet-repeat alleles. Ann. Neurol. 56, 898\u2013901 (2004).","journal-title":"Ann. Neurol."},{"key":"634_CR8","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/hmg\/6.8.1261","volume":"6","author":"L Montermini","year":"1997","unstructured":"Montermini, L. et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum. Mol. Genet. 6, 1261\u20131266 (1997).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.celrep.2016.06.075","volume":"16","author":"J Gerhardt","year":"2016","unstructured":"Gerhardt, J. et al. Stalled DNA replication forks at the endogenous GAA repeats drive repeat expansion in Friedreich\u2019s ataxia cells. Cell Rep. 16, 1218\u20131227 (2016).","journal-title":"Cell Rep."},{"key":"634_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ana.21052","volume":"61","author":"I De Biase","year":"2007","unstructured":"De Biase, I. et al. Progressive GAA expansions in dorsal root ganglia of Friedreich\u2019s ataxia patients. Ann. Neurol. 61, 55\u201360 (2007).","journal-title":"Ann. Neurol."},{"key":"634_CR11","doi-asserted-by":"publisher","first-page":"e63958","DOI":"10.1371\/journal.pone.0063958","volume":"8","author":"HL Plasterer","year":"2013","unstructured":"Plasterer, H. L. et al. Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich\u2019s ataxia. PLoS ONE 8, e63958 (2013).","journal-title":"PLoS ONE"},{"key":"634_CR12","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.nbd.2019.104606","volume":"132","author":"MB Delatycki","year":"2019","unstructured":"Delatycki, M. B. & Bidichandani, S. I. Friedreich ataxia \u2014 pathogenesis and implications for therapies. Neurobiol. Dis. 132, 104606 (2019).","journal-title":"Neurobiol. Dis."},{"key":"634_CR13","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1093\/hmg\/ddaa267","volume":"29","author":"LN Rodden","year":"2021","unstructured":"Rodden, L. N. et al. Methylated and unmethylated epialleles support variegated epigenetic silencing in Friedreich ataxia. Hum. Mol. Genet. 29, 3818\u20133829 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S1474-4422(16)30287-3","volume":"15","author":"K Reetz","year":"2016","unstructured":"Reetz, K. et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurol. 15, 1346\u20131354 (2016).","journal-title":"Lancet Neurol."},{"key":"634_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/mds.26382","volume":"31","author":"C Lecocq","year":"2016","unstructured":"Lecocq, C. et al. Delayed-onset Friedreich\u2019s ataxia revisited. Mov. Disord. 31, 62\u201369 (2016).","journal-title":"Mov. Disord."},{"key":"634_CR16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","volume":"14","author":"K Reetz","year":"2015","unstructured":"Reetz, K. et al. Biological and clinical characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 14, 174\u2013182 (2015).","journal-title":"Lancet Neurol."},{"key":"634_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1093\/jnen\/nlx087","volume":"76","author":"AH Koeppen","year":"2017","unstructured":"Koeppen, A. H., Becker, A. B., Qian, J., Gelman, B. B. & Mazurkiewicz, J. E. Friedreich ataxia: developmental failure of the dorsal root entry zone. J. Neuropathol. Exp. Neurol. 76, 969\u2013977 (2017).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"634_CR18","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1212\/NXG.0000000000000415","volume":"6","author":"M Pandolfo","year":"2020","unstructured":"Pandolfo, M. Neurologic outcomes in Friedreich ataxia: study of a single-site cohort. Neurol. Genet. 6, e415 (2020).","journal-title":"Neurol. Genet."},{"key":"634_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01475-9","volume":"15","author":"E Indelicato","year":"2020","unstructured":"Indelicato, E. et al. Onset features and time to diagnosis in Friedreich\u2019s ataxia. Orphanet J. Rare Dis. 15, 198 (2020).","journal-title":"Orphanet J. Rare Dis."},{"key":"634_CR20","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaneurol.2015.1855","volume":"72","author":"F Pousset","year":"2015","unstructured":"Pousset, F. et al. A 22-year follow-up study of long-term cardiac outcome and predictors of survival in Friedreich ataxia. JAMA Neurol. 72, 1334\u20131341 (2015). This study demonstrates the evolution of long-term cardiac complications and predictors of survival in patients with Friedreich ataxia.","journal-title":"JAMA Neurol."},{"key":"634_CR21","doi-asserted-by":"publisher","first-page":"e0246633","DOI":"10.1371\/journal.pone.0246633","volume":"16","author":"KAG Takazaki","year":"2021","unstructured":"Takazaki, K. A. G. et al. Pre-clinical left ventricular myocardial remodeling in patients with Friedreich\u2019s ataxia: a cardiac MRI study. PLoS ONE 16, e0246633 (2021).","journal-title":"PLoS ONE"},{"key":"634_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4330\/wjc.v11.i1.1","volume":"11","author":"E Hanson","year":"2019","unstructured":"Hanson, E., Sheldon, M., Pacheco, B., Alkubeysi, M. & Raizada, V. Heart disease in Friedreich\u2019s ataxia. World J. Cardiol. 11, 1\u201312 (2019).","journal-title":"World J. Cardiol."},{"key":"634_CR23","doi-asserted-by":"publisher","first-page":"e0116396","DOI":"10.1371\/journal.pone.0116396","volume":"10","author":"AH Koeppen","year":"2015","unstructured":"Koeppen, A. H. et al. The pathogenesis of cardiomyopathy in Friedreich ataxia. PLoS ONE 10, e0116396 (2015).","journal-title":"PLoS ONE"},{"key":"634_CR24","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1212\/NXG.0000000000000250","volume":"4","author":"AG Hamedani","year":"2018","unstructured":"Hamedani, A. G. et al. Longitudinal analysis of contrast acuity in Friedreich ataxia. Neurol. Genet. 4, e250 (2018).","journal-title":"Neurol. Genet."},{"key":"634_CR25","first-page":"1312","volume":"19","author":"M Pandolfo","year":"2013","unstructured":"Pandolfo, M. & Manto, M. Cerebellar and afferent ataxias. Continuum 19, 1312\u20131343 (2013).","journal-title":"Continuum"},{"key":"634_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/acn3.332","volume":"3","author":"M Patel","year":"2016","unstructured":"Patel, M. et al. Progression of Friedreich ataxia: quantitative characterization over 5 years. Ann. Clin. Transl. Neurol. 3, 684\u2013694 (2016). This article presents the 5-year longitudinal data in the FA-COMS study, a large international collaborative study on the natural history of Friedreich ataxia.","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1212\/NXG.0000000000000371","volume":"5","author":"C Rummey","year":"2019","unstructured":"Rummey, C. et al. Psychometric properties of the Friedreich ataxia rating scale. Neurol. Genet. 5, 371 (2019).","journal-title":"Neurol. Genet."},{"key":"634_CR28","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(21)00027-2","volume":"20","author":"K Reetz","year":"2021","unstructured":"Reetz, K. et al. Progression characteristics of the European Friedreich\u2019s Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol. 20, 362\u2013372 (2021). This article presents the 4-year follow-up data in the EFACTS study, a large European study of patients with Friedreich ataxia, including assessment of the sensitivity to change of different outcome scales.","journal-title":"Lancet Neurol."},{"key":"634_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/acn3.51079","volume":"7","author":"G Naeije","year":"2020","unstructured":"Naeije, G. et al. Cerebellar cognitive disorder parallels cerebellar motor symptoms in Friedreich ataxia. Ann. Clin. Transl. Neurol. 7, 1050\u20131054 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12311-019-01068-8","volume":"19","author":"GPD Argyropoulos","year":"2020","unstructured":"Argyropoulos, G. P. D. et al. The cerebellar cognitive affective\/Schmahmann syndrome: a task force paper. Cerebellum 19, 102\u2013125 (2020).","journal-title":"Cerebellum"},{"key":"634_CR31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ana.25355","volume":"84","author":"OE Pagovich","year":"2018","unstructured":"Pagovich, O. E. et al. Corneal confocal microscopy: neurologic disease biomarker in Friedreich ataxia. Ann. Neurol. 84, 893\u2013904 (2018).","journal-title":"Ann. Neurol."},{"key":"634_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/NEN.0b013e31827e5762","volume":"72","author":"AH Koeppen","year":"2013","unstructured":"Koeppen, A. H. & Mazurkiewicz, J. E. Friedreich ataxia: neuropathology revised. J. Neuropathol. Exp. Neurol. 72, 78\u201390 (2013).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"634_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-010-0675-0","volume":"120","author":"JA Morral","year":"2010","unstructured":"Morral, J. A., Davis, A. N., Qian, J., Gelman, B. B. & Koeppen, A. H. Pathology and pathogenesis of sensory neuropathy in Friedreich\u2019s ataxia. Acta Neuropathol. 120, 97\u2013108 (2010).","journal-title":"Acta Neuropathol."},{"key":"634_CR34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jnen\/nlx087","volume":"76","author":"AH Koeppen","year":"2017","unstructured":"Koeppen, A. H., Becker, A. B., Qian, J. & Feustel, P. J. Friedreich ataxia: hypoplasia of spinal cord and dorsal root ganglia. J. Neuropathol. Exp. Neurol. 76, 101\u2013108 (2017).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"634_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-016-0326-3","volume":"4","author":"KC Kemp","year":"2016","unstructured":"Kemp, K. C. et al. Purkinje cell injury, structural plasticity and fusion in patients with Friedreich\u2019s ataxia. Acta Neuropathol. Commun. 4, 53 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"634_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou, A. Y. et al. Mortality in Friedreich ataxia. J. Neurol. Sci. 307, 46\u201349 (2011).","journal-title":"J. Neurol. Sci."},{"key":"634_CR37","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1001\/archneur.62.12.1865","volume":"62","author":"R Bhidayasiri","year":"2005","unstructured":"Bhidayasiri, R., Perlman, S. L., Pulst, S. M. & Geschwind, D. H. Late-onset Friedreich ataxia: phenotypic analysis, magnetic resonance imaging findings, and review of the literature. Arch. Neurol. 62, 1865\u20131869 (2005).","journal-title":"Arch. Neurol."},{"key":"634_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s004150050362","volume":"246","author":"G Coppola","year":"1999","unstructured":"Coppola, G. et al. Why do some Friedreich\u2019s ataxia patients retain tendon reflexes? A clinical, neurophysiological and molecular study. J. Neurol. 246, 353\u2013357 (1999).","journal-title":"J. Neurol."},{"key":"634_CR39","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ana.24595","volume":"79","author":"CA Galea","year":"2016","unstructured":"Galea, C. A. et al. Compound heterozygous FXN mutations and clinical outcome in Friedreich ataxia. Ann. Neurol. 79, 485\u2013495 (2016).","journal-title":"Ann. Neurol."},{"key":"634_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s004399900142","volume":"105","author":"MB Delatycki","year":"1999","unstructured":"Delatycki, M. B. et al. G130V, a common FRDA point mutation, appears to have arisen from a common founder. Hum. Genet. 105, 343\u2013346 (1999).","journal-title":"Hum. Genet."},{"key":"634_CR41","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/1531-8249(199902)45:2<200::AID-ANA10>3.0.CO;2-U","volume":"45","author":"M Cossee","year":"1999","unstructured":"Cossee, M. et al. Friedreich\u2019s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann. Neurol. 45, 200\u2013206 (1999).","journal-title":"Ann. Neurol."},{"key":"634_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/ene.13843","volume":"26","author":"TJR Rezende","year":"2019","unstructured":"Rezende, T. J. R. et al. Developmental and neurodegenerative damage in Friedreich\u2019s ataxia. Eur. J. Neurol. 26, 483\u2013489 (2019).","journal-title":"Eur. J. Neurol."},{"key":"634_CR43","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.neubiorev.2017.08.006","volume":"84","author":"LP Selvadurai","year":"2018","unstructured":"Selvadurai, L. P., Harding, I. H., Corben, L. A. & Georgiou-Karistianis, N. Cerebral abnormalities in Friedreich ataxia: a review. Neurosci. Biobehav. Rev. 84, 394\u2013406 (2018).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"634_CR44","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/ana.26200","volume":"90","author":"IH Harding","year":"2021","unstructured":"Harding, I. H. et al. Brain structure and degeneration staging in Friedreich ataxia: magnetic resonance imaging volumetrics from the ENIGMA-ataxia working group. Ann. Neurol. 90, 570\u2013583 (2021). Results of a large-scale international collaboration on imaging findings in Friedreich ataxia, covering the whole spectrum of findings according to age at onset and disease duration.","journal-title":"Ann. Neurol."},{"key":"634_CR45","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hbm.24921","volume":"41","author":"LP Selvadurai","year":"2020","unstructured":"Selvadurai, L. P. et al. Multiple mechanisms underpin cerebral and cerebellar white matter deficits in Friedreich ataxia: the IMAGE-FRDA study. Hum. Brain Mapp. 41, 1920\u20131933 (2020).","journal-title":"Hum. Brain Mapp."},{"key":"634_CR46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/mds.26436","volume":"31","author":"TJ Rezende","year":"2016","unstructured":"Rezende, T. J. et al. Longitudinal magnetic resonance imaging study shows progressive pyramidal and callosal damage in Friedreich\u2019s ataxia. Mov. Disord. 31, 70\u201378 (2016).","journal-title":"Mov. Disord."},{"key":"634_CR47","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3389\/fneur.2018.00747","volume":"9","author":"M Vavla","year":"2018","unstructured":"Vavla, M. et al. Functional and structural brain damage in Friedreich\u2019s ataxia. Front. Neurol. 9, 747 (2018).","journal-title":"Front. Neurol."},{"key":"634_CR48","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1007\/s00415-021-10512-x","volume":"268","author":"LP Selvadurai","year":"2021","unstructured":"Selvadurai, L. P. et al. Longitudinal structural brain changes in Friedreich ataxia depend on disease severity: the IMAGE-FRDA study. J. Neurol. 268, 4178\u20134189 (2021).","journal-title":"J. Neurol."},{"key":"634_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41588-019-0372-4","volume":"51","author":"A Cortese","year":"2019","unstructured":"Cortese, A. et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat. Genet. 51, 649\u2013658 (2019). In this study, RFC1 intronic expansions were identified as the underlying genetic defect in CANVAS and the clinical spectrum.","journal-title":"Nat. Genet."},{"key":"634_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ajhg.2019.05.016","volume":"105","author":"H Rafehi","year":"2019","unstructured":"Rafehi, H. et al. Bioinformatics-based identification of expanded repeats: a non-reference intronic pentamer expansion in RFC1 Causes CANVAS. Am. J. Hum. Genet. 105, 151\u2013165 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"634_CR51","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1093\/brain\/awaa203","volume":"143","author":"SJ Beecroft","year":"2020","unstructured":"Beecroft, S. J. et al. A Maori specific RFC1 pathogenic repeat configuration in CANVAS, likely due to a founder allele. Brain 143, 2673\u20132680 (2020).","journal-title":"Brain"},{"key":"634_CR52","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1093\/brain\/awaa263","volume":"143","author":"CK Scriba","year":"2020","unstructured":"Scriba, C. K. et al. A novel RFC1 repeat motif (ACAGG) in two Asia-Pacific CANVAS families. Brain 143, 2904\u20132910 (2020).","journal-title":"Brain"},{"key":"634_CR53","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s10038-020-0807-x","volume":"65","author":"M Tsuchiya","year":"2020","unstructured":"Tsuchiya, M. et al. RFC1 repeat expansion in Japanese patients with late-onset cerebellar ataxia. J. Hum. Genet. 65, 1143\u20131147 (2020).","journal-title":"J. Hum. Genet."},{"key":"634_CR54","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/mds.28074","volume":"35","author":"R Sullivan","year":"2020","unstructured":"Sullivan, R. et al. RFC1 intronic repeat expansions absent in pathologically confirmed multiple systems atrophy. Mov. Disord. 35, 1277\u20131279 (2020).","journal-title":"Mov. Disord."},{"key":"634_CR55","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ana.25902","volume":"88","author":"L Wan","year":"2020","unstructured":"Wan, L. et al. Biallelic intronic AAGGG expansion of RFC1 is related to multiple system atrophy. Ann. Neurol. 88, 1132\u20131143 (2020).","journal-title":"Ann. Neurol."},{"key":"634_CR56","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3389\/fgene.2019.01219","volume":"10","author":"F Akcimen","year":"2019","unstructured":"Akcimen, F. et al. Investigation of the RFC1 repeat expansion in a Canadian and a Brazilian ataxia cohort: identification of novel conformations. Front. Genet. 10, 1219 (2019).","journal-title":"Front. Genet."},{"key":"634_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.parkreldis.2020.02.017","volume":"73","author":"Y Fan","year":"2020","unstructured":"Fan, Y. et al. No biallelic intronic AAGGG repeat expansion in RFC1 was found in patients with late-onset ataxia and MSA. Parkinsonism Relat. Disord. 73, 1\u20132 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"634_CR58","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/jnnp-2020-323998","volume":"91","author":"SH Van Daele","year":"2020","unstructured":"Van Daele, S. H. et al. Diagnostic yield of testing for RFC1 repeat expansions in patients with unexplained adult-onset cerebellar ataxia. J. Neurol. Neurosurg. Psychiatry 91, 1233\u20131234 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"634_CR59","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1212\/NXG.0000000000000440","volume":"6","author":"D Aboud Syriani","year":"2020","unstructured":"Aboud Syriani, D. et al. Prevalence of RFC1-mediated spinocerebellar ataxia in a North American ataxia cohort. Neurol. Genet. 6, e440 (2020).","journal-title":"Neurol. Genet."},{"key":"634_CR60","doi-asserted-by":"publisher","first-page":"E7109","DOI":"10.1073\/pnas.1807334115","volume":"115","author":"DA Kiktev","year":"2018","unstructured":"Kiktev, D. A., Sheng, Z., Lobachev, K. S. & Petes, T. D. GC content elevates mutation and recombination rates in the yeast Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 115, E7109\u2013E7118 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR61","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1093\/nar\/gkz501","volume":"47","author":"N Mousavi","year":"2019","unstructured":"Mousavi, N., Shleizer-Burko, S., Yanicky, R. & Gymrek, M. Profiling the genome-wide landscape of tandem repeat expansions. Nucleic Acids Res. 47, e90 (2019).","journal-title":"Nucleic Acids Res."},{"key":"634_CR62","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1534\/genetics.118.301672","volume":"210","author":"M Abu Diab","year":"2018","unstructured":"Abu Diab, M. et al. The G-rich repeats in FMR1 and C9orf72 loci are hotspots for local unpairing of DNA. Genetics 210, 1239\u20131252 (2018).","journal-title":"Genetics"},{"key":"634_CR63","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/brain\/awz418","volume":"143","author":"A Cortese","year":"2020","unstructured":"Cortese, A. et al. Cerebellar ataxia, neuropathy, vestibular areflexia syndrome due to RFC1 repeat expansion. Brain 143, 480\u2013490 (2020). This article presents the largest series of patients with biallelic RFC1 mutations published so far, with detailed clinical phenotyping.","journal-title":"Brain"},{"key":"634_CR64","doi-asserted-by":"publisher","first-page":"e1369","DOI":"10.1212\/WNL.0000000000011528","volume":"96","author":"A Traschutz","year":"2021","unstructured":"Traschutz, A. et al. Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease. Neurology 96, e1369\u2013e1382 (2021).","journal-title":"Neurology"},{"key":"634_CR65","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/brain\/awab072","volume":"144","author":"R Curro","year":"2021","unstructured":"Curro, R. et al. RFC1 expansions are a common cause of idiopathic sensory neuropathy. Brain 144, 1542\u20131550 (2021). This article shows the phenotypic variability of biallelic RFC1 mutations and details the sensory involvement.","journal-title":"Brain"},{"key":"634_CR66","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1212\/WNL.0b013e31821d746e","volume":"76","author":"DJ Szmulewicz","year":"2011","unstructured":"Szmulewicz, D. J. et al. Sensory neuropathy as part of the cerebellar ataxia neuropathy vestibular areflexia syndrome. Neurology 76, 1903\u20131910 (2011).","journal-title":"Neurology"},{"key":"634_CR67","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1007\/s00415-021-10499-5","volume":"268","author":"S Montaut","year":"2021","unstructured":"Montaut, S. et al. Biallelic RFC1-expansion in a French multicentric sporadic ataxia cohort. J. Neurol. 268, 3337\u20133343 (2021).","journal-title":"J. Neurol."},{"key":"634_CR68","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1212\/WNL.0000000000000352","volume":"82","author":"DJ Szmulewicz","year":"2014","unstructured":"Szmulewicz, D. J. et al. Dorsal root ganglionopathy is responsible for the sensory impairment in CANVAS. Neurology 82, 1410\u20131415 (2014). This article details the neuropathological findings of CANVAS and identifies the ganglionopathy as responsible for sensory involvement.","journal-title":"Neurology"},{"key":"634_CR69","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jns.2018.01.023","volume":"387","author":"D Burke","year":"2018","unstructured":"Burke, D. & Halmagyi, G. M. Normal tendon reflexes despite absent sensory nerve action potentials in CANVAS: a neurophysiological study. J. Neurol. Sci. 387, 75\u201379 (2018).","journal-title":"J. Neurol. Sci."},{"key":"634_CR70","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1212\/01.WNL.0000125287.98456.23","volume":"62","author":"RH Baloh","year":"2004","unstructured":"Baloh, R. H., Jen, J. C., Kim, G. & Baloh, R. W. Chronic cough due to Thr124Met mutation in the peripheral myelin protein zero (MPZ gene). Neurology 62, 1905\u20131906 (2004).","journal-title":"Neurology"},{"key":"634_CR71","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/ene.13563","volume":"25","author":"L Pelosi","year":"2018","unstructured":"Pelosi, L. et al. Peripheral nerves are pathologically small in cerebellar ataxia neuropathy vestibular areflexia syndrome: a controlled ultrasound study. Eur. J. Neurol. 25, 659\u2013665 (2018).","journal-title":"Eur. J. Neurol."},{"key":"634_CR72","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1093\/brain\/awaa244","volume":"143","author":"KR Kumar","year":"2020","unstructured":"Kumar, K. R. et al. RFC1 expansions can mimic hereditary sensory neuropathy with cough and Sjogren syndrome. Brain 143, e82 (2020).","journal-title":"Brain"},{"key":"634_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab449","author":"V Huin","year":"2021","unstructured":"Huin, V. et al. Motor neuron pathology in CANVAS due to RFC1 expansions. Brain https:\/\/doi.org\/10.1093\/brain\/awab449 (2021).","journal-title":"Brain"},{"key":"634_CR74","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/brain\/awt339","volume":"137","author":"G El Euch-Fayache","year":"2014","unstructured":"El Euch-Fayache, G., Bouhlal, Y., Amouri, R., Feki, M. & Hentati, F. Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. Brain 137, 402\u2013410 (2014).","journal-title":"Brain"},{"key":"634_CR75","doi-asserted-by":"publisher","first-page":"374","DOI":"10.5334\/tohm.298","volume":"6","author":"AE Becker","year":"2016","unstructured":"Becker, A. E., Vargas, W. & Pearson, T. S. Ataxia with vitamin E deficiency may present with cervical dystonia. Tremor Other Hyperkinet. Mov. 6, 374 (2016).","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"634_CR76","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/ana.410410621","volume":"41","author":"T Yokota","year":"1997","unstructured":"Yokota, T. et al. Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene. Ann. Neurol. 41, 826\u2013832 (1997).","journal-title":"Ann. Neurol."},{"key":"634_CR77","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s004010050662","volume":"93","author":"A Larnaout","year":"1997","unstructured":"Larnaout, A. et al. Friedreich\u2019s ataxia with isolated vitamin E deficiency: a neuropathological study of a Tunisian patient. Acta Neuropathol. 93, 633\u2013637 (1997).","journal-title":"Acta Neuropathol."},{"key":"634_CR78","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1046\/j.1468-1331.2001.00273.x","volume":"8","author":"S Gabsi","year":"2001","unstructured":"Gabsi, S. et al. Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. Eur. J. Neurol. 8, 477\u2013481 (2001).","journal-title":"Eur. J. Neurol."},{"key":"634_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41582-018-0101-0","volume":"15","author":"S Rahman","year":"2019","unstructured":"Rahman, S. & Copeland, W. C. POLG-related disorders and their neurological manifestations. Nat. Rev. Neurol. 15, 40\u201352 (2019). This article presents the wide spectrum of neurological manifestations associated with POLG mutations.","journal-title":"Nat. Rev. Neurol."},{"key":"634_CR80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/brain\/awr326","volume":"135","author":"NZ Lax","year":"2012","unstructured":"Lax, N. Z. et al. Sensory neuronopathy in patients harbouring recessive polymerase gamma mutations. Brain 135, 62\u201371 (2012).","journal-title":"Brain"},{"key":"634_CR81","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.nmd.2016.02.008","volume":"26","author":"M Mancuso","year":"2016","unstructured":"Mancuso, M. et al. \u201cMitochondrial neuropathies\u201d: a survey from the large cohort of the Italian Network. Neuromuscul. Disord. 26, 272\u2013276 (2016).","journal-title":"Neuromuscul. Disord."},{"key":"634_CR82","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s12311-012-0378-2","volume":"11","author":"M Synofzik","year":"2012","unstructured":"Synofzik, M., Srulijes, K., Godau, J., Berg, D. & Schols, L. Characterizing POLG ataxia: clinics, electrophysiology and imaging. Cerebellum 11, 1002\u20131011 (2012).","journal-title":"Cerebellum"},{"key":"634_CR83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0022-510X(98)00249-4","volume":"161","author":"T Lonnqvist","year":"1998","unstructured":"Lonnqvist, T., Paetau, A., Nikali, K., von Boguslawski, K. & Pihko, H. Infantile onset spinocerebellar ataxia with sensory neuropathy (IOSCA): neuropathological features. J. Neurol. Sci. 161, 57\u201365 (1998).","journal-title":"J. Neurol. Sci."},{"key":"634_CR84","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.661","volume":"6","author":"MG Otero","year":"2019","unstructured":"Otero, M. G. et al. Novel pathogenic COX20 variants causing dysarthria, ataxia, and sensory neuropathy. Ann. Clin. Transl. Neurol. 6, 154\u2013160 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR85","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1093\/brain\/awab135","volume":"144","author":"HL Dong","year":"2021","unstructured":"Dong, H. L. et al. Bi-allelic loss of function variants in COX20 gene cause autosomal recessive sensory neuronopathy. Brain 144, 2457\u20132470 (2021).","journal-title":"Brain"},{"key":"634_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-41","volume":"8","author":"M Synofzik","year":"2013","unstructured":"Synofzik, M. et al. Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrum. Orphanet J. Rare Dis. 8, 41 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"634_CR87","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/mds.25604","volume":"28","author":"A Duquette","year":"2013","unstructured":"Duquette, A., Brais, B., Bouchard, J. P. & Mathieu, J. Clinical presentation and early evolution of spastic ataxia of Charlevoix-Saguenay. Mov. Disord. 28, 2011\u20132014 (2013).","journal-title":"Mov. Disord."},{"key":"634_CR88","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/mds.27319","volume":"33","author":"A Levy","year":"2018","unstructured":"Levy, A. & Lang, A. E. Ataxia-telangiectasia: a review of movement disorders, clinical features, and genotype correlations. Mov. Disord. 33, 1238\u20131247 (2018).","journal-title":"Mov. Disord."},{"key":"634_CR89","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.2014.56.5101","volume":"33","author":"F Suarez","year":"2015","unstructured":"Suarez, F. et al. Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. J. Clin. Oncol. 33, 202\u2013208 (2015).","journal-title":"J. Clin. Oncol."},{"key":"634_CR90","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1093\/brain\/awp211","volume":"132","author":"M Anheim","year":"2009","unstructured":"Anheim, M. et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype\/phenotype correlation study of a cohort of 90 patients. Brain 132, 2688\u20132698 (2009).","journal-title":"Brain"},{"key":"634_CR91","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ejrad.2018.11.035","volume":"110","author":"S Ronsin","year":"2019","unstructured":"Ronsin, S. et al. A new MRI marker of ataxia with oculomotor apraxia. Eur. J. Radiol. 110, 187\u2013192 (2019).","journal-title":"Eur. J. Radiol."},{"key":"634_CR92","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/archneur.61.2.257","volume":"61","author":"BP van de Warrenburg","year":"2004","unstructured":"van de Warrenburg, B. P. et al. Peripheral nerve involvement in spinocerebellar ataxias. Arch. Neurol. 61, 257\u2013261 (2004). This study details peripheral nerve involvement in dominant spinocerebellar ataxias.","journal-title":"Arch. Neurol."},{"key":"634_CR93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/mus.26613","volume":"60","author":"L Pelosi","year":"2019","unstructured":"Pelosi, L. et al. Spinocerebellar ataxia type 2-neuronopathy or neuropathy? Muscle Nerve 60, 271\u2013278 (2019).","journal-title":"Muscle Nerve"},{"key":"634_CR94","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.clinph.2017.09.114","volume":"128","author":"L Pelosi","year":"2017","unstructured":"Pelosi, L., Mulroy, E., Rodrigues, M. J. & Roxburgh, R. H. Neuronopathy and neuropathy in autosomal dominant spino-cerebellar ataxia (SCA): a preliminary peripheral nerve ultrasound study. Clin. Neurophysiol. 128, 2436\u20132437 (2017).","journal-title":"Clin. Neurophysiol."},{"key":"634_CR95","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s004010050989","volume":"97","author":"R Estrada","year":"1999","unstructured":"Estrada, R., Galarraga, J., Orozco, G., Nodarse, A. & Auburger, G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 97, 306\u2013310 (1999).","journal-title":"Acta Neuropathol."},{"key":"634_CR96","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.neuron.2019.01.049","volume":"101","author":"M Synofzik","year":"2019","unstructured":"Synofzik, M., Puccio, H., Mochel, F. & Sch\u00f6ls, L. Autosomal recessive cerebellar ataxias: paving the way toward targeted molecular therapies. Neuron 101, 560\u2013583 (2019). An in-depth review of the pathophysiological mechanisms involved in recessive cerebellar ataxias.","journal-title":"Neuron"},{"key":"634_CR97","doi-asserted-by":"publisher","first-page":"e21362","DOI":"10.1096\/fj.202000524RR","volume":"35","author":"D Doni","year":"2021","unstructured":"Doni, D. et al. The displacement of frataxin from the mitochondrial cristae correlates with abnormal respiratory supercomplexes formation and bioenergetic defects in cells of Friedreich ataxia patients. FASEB J. 35, e21362 (2021).","journal-title":"FASEB J."},{"key":"634_CR98","doi-asserted-by":"publisher","first-page":"NS20200093","DOI":"10.1042\/NS20200093","volume":"5","author":"DR Lynch","year":"2021","unstructured":"Lynch, D. R. & Farmer, G. Mitochondrial and metabolic dysfunction in Friedreich ataxia: update on pathophysiological relevance and clinical interventions. Neuronal Signal. 5, NS20200093 (2021).","journal-title":"Neuronal Signal."},{"key":"634_CR99","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1089\/ars.2012.4537","volume":"19","author":"Y Shan","year":"2013","unstructured":"Shan, Y. et al. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich\u2019s ataxia YG8R mouse model. Antioxid. Redox Signal. 19, 1481\u20131493 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"634_CR100","doi-asserted-by":"publisher","first-page":"7853","DOI":"10.3390\/ijms14047853","volume":"14","author":"V D\u2019Oria","year":"2013","unstructured":"D\u2019Oria, V. et al. Frataxin deficiency leads to reduced expression and impaired translocation of NF-E2-related factor (Nrf2) in cultured motor neurons. Int. J. Mol. Sci. 14, 7853\u20137865 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"634_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","volume":"303","author":"AH Koeppen","year":"2011","unstructured":"Koeppen, A. H. Friedreich\u2019s ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303, 1\u201312 (2011).","journal-title":"J. Neurol. Sci."},{"key":"634_CR102","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cmet.2015.01.010","volume":"21","author":"A Martelli","year":"2015","unstructured":"Martelli, A. et al. Iron regulatory protein 1 sustains mitochondrial iron loading and function in frataxin deficiency. Cell Metab. 21, 311\u2013323 (2015).","journal-title":"Cell Metab."},{"key":"634_CR103","doi-asserted-by":"publisher","first-page":"101483","DOI":"10.1016\/j.redox.2020.101483","volume":"32","author":"J Du","year":"2020","unstructured":"Du, J. et al. Identification of Frataxin as a regulator of ferroptosis. Redox Biol. 32, 101483 (2020).","journal-title":"Redox Biol."},{"key":"634_CR104","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1093\/hmg\/ddn280","volume":"17","author":"AH Hakonen","year":"2008","unstructured":"Hakonen, A. H. et al. Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. Hum. Mol. Genet. 17, 3822\u20133835 (2008).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR105","doi-asserted-by":"publisher","first-page":"e00755","DOI":"10.1002\/prp2.755","volume":"9","author":"J Johnson","year":"2021","unstructured":"Johnson, J., Mercado-Ayon, E., Clark, E., Lynch, D. & Lin, H. Drp1-dependent peptide reverse mitochondrial fragmentation, a homeostatic response in Friedreich ataxia. Pharmacol. Res. Perspect. 9, e00755 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"key":"634_CR106","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/hmg\/ddw173","volume":"25","author":"TY Bradshaw","year":"2016","unstructured":"Bradshaw, T. Y. et al. A reduction in Drp1-mediated fission compromises mitochondrial health in autosomal recessive spastic ataxia of Charlevoix Saguenay. Hum. Mol. Genet. 25, 3232\u20133244 (2016).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR107","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1073\/pnas.1113166109","volume":"109","author":"M Girard","year":"2012","unstructured":"Girard, M. et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc. Natl Acad. Sci. USA 109, 1661\u20131666 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR108","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/genes8020052","volume":"8","author":"Y Shiomi","year":"2017","unstructured":"Shiomi, Y. & Nishitani, H. Control of genome integrity by RFC complexes; conductors of PCNA loading onto and unloading from chromatin during DNA replication. Genes 8, 52 (2017).","journal-title":"Genes"},{"key":"634_CR109","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13578-020-00398-z","volume":"10","author":"W Zhang","year":"2020","unstructured":"Zhang, W., Feng, J. & Li, Q. The replisome guides nucleosome assembly during DNA replication. Cell Biosci. 10, 37 (2020).","journal-title":"Cell Biosci."},{"key":"634_CR110","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1128\/MCB.00285-10","volume":"30","author":"RM Overmeer","year":"2010","unstructured":"Overmeer, R. M. et al. Replication factor C recruits DNA polymerase delta to sites of nucleotide excision repair but is not required for PCNA recruitment. Mol. Cell Biol. 30, 4828\u20134839 (2010).","journal-title":"Mol. Cell Biol."},{"key":"634_CR111","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1021\/bi00015a012","volume":"34","author":"MK Shivji","year":"1995","unstructured":"Shivji, M. K., Podust, V. N., Hubscher, U. & Wood, R. D. Nucleotide excision repair DNA synthesis by DNA polymerase epsilon in the presence of PCNA, RFC, and RPA. Biochemistry 34, 5011\u20135017 (1995).","journal-title":"Biochemistry"},{"key":"634_CR112","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molcel.2018.05.014","volume":"71","author":"S Juhasz","year":"2018","unstructured":"Juhasz, S., Elbakry, A., Mathes, A. & Lobrich, M. ATRX Promotes DNA repair synthesis and sister chromatid exchange during homologous recombination. Mol. Cell 71, 11\u201324.e7 (2018).","journal-title":"Mol. Cell"},{"key":"634_CR113","doi-asserted-by":"publisher","first-page":"e2912","DOI":"10.1212\/WNL.0000000000010744","volume":"95","author":"M Gisatulin","year":"2020","unstructured":"Gisatulin, M. et al. Clinical spectrum of the pentanucleotide repeat expansion in the RFC1 gene in ataxia syndromes. Neurology 95, e2912\u2013e2923 (2020).","journal-title":"Neurology"},{"key":"634_CR114","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cells9091969","volume":"9","author":"L Pizzamiglio","year":"2020","unstructured":"Pizzamiglio, L., Focchi, E. & Antonucci, F. ATM protein kinase: old and new implications in neuronal pathways and brain circuitry. Cells 9, 1969 (2020).","journal-title":"Cells"},{"key":"634_CR115","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nrg2380","volume":"9","author":"KW Caldecott","year":"2008","unstructured":"Caldecott, K. W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 9, 619\u2013631 (2008).","journal-title":"Nat. Rev. Genet."},{"key":"634_CR116","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1126\/science.1192912","volume":"330","author":"Z Guo","year":"2010","unstructured":"Guo, Z., Kozlov, S., Lavin, M. F., Person, M. D. & Paull, T. T. ATM activation by oxidative stress. Science 330, 517\u2013521 (2010). A landmark paper on the role of ATM in regulating oxidative stress.","journal-title":"Science"},{"key":"634_CR117","doi-asserted-by":"publisher","first-page":"eaax9778","DOI":"10.1126\/sciadv.aax9778","volume":"5","author":"A Ghosh","year":"2019","unstructured":"Ghosh, A. et al. SCAN1-TDP1 trapping on mitochondrial DNA promotes mitochondrial dysfunction and mitophagy. Sci. Adv. 5, eaax9778 (2019).","journal-title":"Sci. Adv."},{"key":"634_CR118","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1073\/pnas.1100084108","volume":"108","author":"P Sykora","year":"2011","unstructured":"Sykora, P., Croteau, D. L., Bohr, V. A. & Wilson, D. M. 3rd Aprataxin localizes to mitochondria and preserves mitochondrial function. Proc. Natl Acad. Sci. USA 108, 7437\u20137442 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"634_CR119","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1093\/nar\/gkr1245","volume":"40","author":"N Tahbaz","year":"2012","unstructured":"Tahbaz, N., Subedi, S. & Weinfeld, M. Role of polynucleotide kinase\/phosphatase in mitochondrial DNA repair. Nucleic Acids Res. 40, 3484\u20133495 (2012).","journal-title":"Nucleic Acids Res."},{"key":"634_CR120","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.bbamcr.2015.01.018","volume":"1853","author":"JO Fuss","year":"2015","unstructured":"Fuss, J. O., Tsai, C. L., Ishida, J. P. & Tainer, J. A. Emerging critical roles of Fe-S clusters in DNA replication and repair. Biochim. Biophys. Acta 1853, 1253\u20131271 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"634_CR121","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/acn3.322","volume":"3","author":"AD Bhalla","year":"2016","unstructured":"Bhalla, A. D., Khodadadi-Jamayran, A., Li, Y., Lynch, D. R. & Napierala, M. Deep sequencing of mitochondrial genomes reveals increased mutation load in Friedreich\u2019s ataxia. Ann. Clin. Transl. Neurol. 3, 523\u2013536 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR122","doi-asserted-by":"publisher","first-page":"103587","DOI":"10.1016\/j.mcn.2020.103587","volume":"111","author":"J Moreno-Lorite","year":"2021","unstructured":"Moreno-Lorite, J., Perez-Luz, S., Katsu-Jimenez, Y., Oberdoerfer, D. & Diaz-Nido, J. DNA repair pathways are altered in neural cell models of frataxin deficiency. Mol. Cell Neurosci. 111, 103587 (2021).","journal-title":"Mol. Cell Neurosci."},{"key":"634_CR123","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/jpm11080708","volume":"11","author":"P Rojas","year":"2021","unstructured":"Rojas, P. et al. Neuro-ophthalmological findings in Friedreich\u2019s ataxia. J. Pers. Med. 11, 708 (2021).","journal-title":"J. Pers. Med."},{"key":"634_CR124","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1042\/BST20200690","volume":"49","author":"LM Castelli","year":"2021","unstructured":"Castelli, L. M., Huang, W. P., Lin, Y. H., Chang, K. Y. & Hautbergue, G. M. Mechanisms of repeat-associated non-AUG translation in neurological microsatellite expansion disorders. Biochem. Soc. Trans. 49, 775\u2013792 (2021).","journal-title":"Biochem. Soc. Trans."},{"key":"634_CR125","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-016-0288-5","volume":"4","author":"AH Koeppen","year":"2016","unstructured":"Koeppen, A. H., Ramirez, R. L., Becker, A. B. & Mazurkiewicz, J. E. Dorsal root ganglia in Friedreich ataxia: satellite cell proliferation and inflammation. Acta Neuropathol. Commun. 4, 46 (2016).","journal-title":"Acta Neuropathol. Commun."},{"key":"634_CR126","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1093\/hmg\/ddy198","volume":"27","author":"D Nachun","year":"2018","unstructured":"Nachun, D. et al. Peripheral blood gene expression reveals an inflammatory transcriptomic signature in Friedreich\u2019s ataxia patients. Hum. Mol. Genet. 27, 2965\u20132977 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR127","doi-asserted-by":"publisher","first-page":"e0209496","DOI":"10.1371\/journal.pone.0209496","volume":"13","author":"SA McGrath-Morrow","year":"2018","unstructured":"McGrath-Morrow, S. A. et al. Inflammation and transcriptional responses of peripheral blood mononuclear cells in classic ataxia telangiectasia. PLoS ONE 13, e0209496 (2018).","journal-title":"PLoS ONE"},{"key":"634_CR128","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","volume":"384","author":"V Libri","year":"2014","unstructured":"Libri, V. et al. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich\u2019s ataxia: an exploratory, open-label, dose-escalation study. Lancet 384, 504\u2013513 (2014).","journal-title":"Lancet"},{"key":"634_CR129","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42466-019-0038-9","volume":"1","author":"K Reetz","year":"2019","unstructured":"Reetz, K. et al. Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurol. Res. Pract. 1, 33 (2019).","journal-title":"Neurol. Res. Pract."},{"key":"634_CR130","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/JMDH.S292945","volume":"14","author":"DR Lynch","year":"2021","unstructured":"Lynch, D. R., Schadt, K., Kichula, E., McCormack, S. & Lin, K. Y. Friedreich ataxia: multidisciplinary clinical care. J. Multidiscip. Healthc. 14, 1645\u20131658 (2021).","journal-title":"J. Multidiscip. Healthc."},{"key":"634_CR131","doi-asserted-by":"publisher","first-page":"e1958","DOI":"10.1371\/journal.pone.0001958","volume":"3","author":"M Rai","year":"2008","unstructured":"Rai, M. et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS ONE 3, e1958 (2008).","journal-title":"PLoS ONE"},{"key":"634_CR132","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/ana.24260","volume":"76","author":"E Soragni","year":"2014","unstructured":"Soragni, E. et al. Epigenetic therapy for Friedreich ataxia. Ann. Neurol. 76, 489\u2013508 (2014).","journal-title":"Ann. Neurol."},{"key":"634_CR133","doi-asserted-by":"publisher","first-page":"17973","DOI":"10.1074\/jbc.RA120.015533","volume":"295","author":"G Vilema-Enriquez","year":"2020","unstructured":"Vilema-Enriquez, G. et al. Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich\u2019s ataxia patient cells. J. Biol. Chem. 295, 17973\u201317985 (2020).","journal-title":"J. Biol. Chem."},{"key":"634_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10606","volume":"7","author":"L Li","year":"2016","unstructured":"Li, L., Matsui, M. & Corey, D. R. Activating frataxin expression by repeat-targeted nucleic acids. Nat. Commun. 7, 10606 (2016).","journal-title":"Nat. Commun."},{"key":"634_CR135","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/nat.2017.0703","volume":"28","author":"L Li","year":"2018","unstructured":"Li, L. et al. Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat. Nucleic Acid. Ther. 28, 23\u201333 (2018).","journal-title":"Nucleic Acid. Ther."},{"key":"634_CR136","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1126\/science.aan6414","volume":"358","author":"GS Erwin","year":"2017","unstructured":"Erwin, G. S. et al. Synthetic transcription elongation factors license transcription across repressive chromatin. Science 358, 1617\u20131622 (2017).","journal-title":"Science"},{"key":"634_CR137","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1093\/hmg\/ddaa282","volume":"29","author":"CK Hui","year":"2021","unstructured":"Hui, C. K., Dedkova, E. N., Montgomery, C. & Cortopassi, G. Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich\u2019s ataxia model mice. Hum. Mol. Genet. 29, 3954\u20133965 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR138","doi-asserted-by":"publisher","first-page":"e0217776","DOI":"10.1371\/journal.pone.0217776","volume":"14","author":"M Jasoliya","year":"2019","unstructured":"Jasoliya, M. et al. Dimethyl fumarate dosing in humans increases frataxin expression: a potential therapy for Friedreich\u2019s ataxia. PLoS ONE 14, e0217776 (2019).","journal-title":"PLoS ONE"},{"key":"634_CR139","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/brain\/awq386","volume":"134","author":"RA Linker","year":"2011","unstructured":"Linker, R. A. et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678\u2013692 (2011).","journal-title":"Brain"},{"key":"634_CR140","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1093\/hmg\/ddx167","volume":"26","author":"G Hayashi","year":"2017","unstructured":"Hayashi, G. et al. Dimethyl fumarate mediates Nrf2-dependent mitochondrial biogenesis in mice and humans. Hum. Mol. Genet. 26, 2864\u20132873 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR141","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/mds.27604","volume":"34","author":"G Alfedi","year":"2019","unstructured":"Alfedi, G. et al. Drug repositioning screening identifies etravirine as a potential therapeutic for Friedreich\u2019s ataxia. Mov. Disord. 34, 323\u2013334 (2019).","journal-title":"Mov. Disord."},{"key":"634_CR142","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/acn3.731","volume":"6","author":"DR Lynch","year":"2019","unstructured":"Lynch, D. R. et al. Randomized, double-blind, placebo-controlled study of interferon- \u03b3 1b in Friedreich ataxia. Ann. Clin. Transl. Neurol. 6, 546\u2013553 (2019).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR143","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12311-008-0036-x","volume":"7","author":"F Acquaviva","year":"2008","unstructured":"Acquaviva, F. et al. Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression. Cerebellum 7, 360\u2013365 (2008).","journal-title":"Cerebellum"},{"key":"634_CR144","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/mds.26552","volume":"31","author":"F Sacca","year":"2016","unstructured":"Sacca, F. et al. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia. Mov. Disord. 31, 734\u2013741 (2016).","journal-title":"Mov. Disord."},{"key":"634_CR145","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuropharm.2017.05.011","volume":"123","author":"JL Miller","year":"2017","unstructured":"Miller, J. L. et al. Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo. Neuropharmacology 123, 34\u201345 (2017).","journal-title":"Neuropharmacology"},{"key":"634_CR146","doi-asserted-by":"publisher","first-page":"e134221","DOI":"10.1172\/jci.insight.134221","volume":"5","author":"M Igoillo-Esteve","year":"2020","unstructured":"Igoillo-Esteve, M. et al. Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia. JCI Insight 5, e134221 (2020).","journal-title":"JCI Insight"},{"key":"634_CR147","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","volume":"21","author":"PM Vyas","year":"2012","unstructured":"Vyas, P. M. et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich\u2019s ataxia mouse model. Hum. Mol. Genet. 21, 1230\u20131247 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"634_CR148","doi-asserted-by":"publisher","DOI":"10.1038\/srep20019","volume":"6","author":"JF Nabhan","year":"2016","unstructured":"Nabhan, J. F. et al. Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich\u2019s ataxia. Sci. Rep. 6, 20019 (2016).","journal-title":"Sci. Rep."},{"key":"634_CR149","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini, M. et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat. Med. 20, 542\u2013547 (2014).","journal-title":"Nat. Med."},{"key":"634_CR150","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","volume":"26","author":"F Piguet","year":"2018","unstructured":"Piguet, F. et al. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol. Ther. 26, 1940\u20131952 (2018).","journal-title":"Mol. Ther."},{"key":"634_CR151","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","volume":"16","author":"JM Gottesfeld","year":"2019","unstructured":"Gottesfeld, J. M. Molecular mechanisms and therapeutics for the GAA.TTC expansion disease Friedreich ataxia. Neurotherapeutics 16, 1032\u20131049 (2019).","journal-title":"Neurotherapeutics"},{"key":"634_CR152","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.3390\/ijms22041815","volume":"22","author":"G Ocana-Santero","year":"2021","unstructured":"Ocana-Santero, G., Diaz-Nido, J. & Herranz-Martin, S. Future prospects of gene therapy for Friedreich\u2019s ataxia. Int. J. Mol. Sci. 22, 1815 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"634_CR153","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch, D. R. et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann. Neurol. 89, 212\u2013225 (2021). This phase II study produced promising results with respect to the efficacy of omaveloxolone, a molecule that targets oxidative stress, in patients with Friedreich ataxia.","journal-title":"Ann. Neurol."},{"key":"634_CR154","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02255435 (2021)."},{"key":"634_CR155","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S1474-4422(07)70220-X","volume":"6","author":"NA Di Prospero","year":"2007","unstructured":"Di Prospero, N. A., Baker, A., Jeffries, N. & Fischbeck, K. H. Neurological effects of high-dose idebenone in patients with Friedreich\u2019s ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878\u2013886 (2007).","journal-title":"Lancet Neurol."},{"key":"634_CR156","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archneurol.2010.168","volume":"67","author":"DR Lynch","year":"2010","unstructured":"Lynch, D. R., Perlman, S. L. & Meier, T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch. Neurol. 67, 941\u2013947 (2010).","journal-title":"Arch. Neurol."},{"key":"634_CR157","first-page":"CD007791","volume":"8","author":"M Kearney","year":"2016","unstructured":"Kearney, M., Orrell, R. W., Fahey, M., Brassington, R. & Pandolfo, M. Pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 8, CD007791 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"634_CR158","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2217\/nmt-2018-0013","volume":"8","author":"T Zesiewicz","year":"2018","unstructured":"Zesiewicz, T. et al. Double-blind, randomized and controlled trial of EPI-743 in Friedreich\u2019s ataxia. Neurodegener. Dis. Manag. 8, 233\u2013242 (2018).","journal-title":"Neurodegener. Dis. Manag."},{"key":"634_CR159","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s00415-015-7719-2","volume":"262","author":"EM Yiu","year":"2015","unstructured":"Yiu, E. M. et al. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 262, 1344\u20131353 (2015).","journal-title":"J. Neurol."},{"key":"634_CR160","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT03933163 (2021)."},{"key":"634_CR161","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mds.27353","volume":"33","author":"T Zesiewicz","year":"2018","unstructured":"Zesiewicz, T. et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich\u2019s ataxia. Mov. Disord. 33, 1000\u20131005 (2018).","journal-title":"Mov. Disord."},{"key":"634_CR162","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT04102501 (2021)."},{"key":"634_CR163","doi-asserted-by":"publisher","first-page":"e10025","DOI":"10.1371\/journal.pone.0010025","volume":"5","author":"D Marmolino","year":"2010","unstructured":"Marmolino, D. et al. PGC-1alpha down-regulation affects the antioxidant response in Friedreich\u2019s ataxia. PLoS ONE 5, e10025 (2010).","journal-title":"PLoS ONE"},{"key":"634_CR164","doi-asserted-by":"publisher","first-page":"105162","DOI":"10.1016\/j.nbd.2020.105162","volume":"148","author":"L Rodriguez-Pascau","year":"2021","unstructured":"Rodriguez-Pascau, L. et al. PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia. Neurobiol. Dis. 148, 105162 (2021).","journal-title":"Neurobiol. Dis."},{"key":"634_CR165","unstructured":"Minoryx Therapeutics. Minoryx\u2019s clinical candidate leriglitazone shows clinical benefit in a proof of concept phase 2 study in Friedreich\u2019s ataxia. Minoryx https:\/\/www.minoryx.com\/media\/minoryx\u2019s_clinical_candidate_leriglitazone_shows_clinical_benefit_in_a_proof_of_concept_phase_2_study_in_friedreichs_ataxia\/ (2020)."},{"key":"634_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10320-2","volume":"7","author":"H Zhao","year":"2017","unstructured":"Zhao, H. et al. Peptide SS-31 upregulates frataxin expression and improves the quality of mitochondria: implications in the treatment of Friedreich ataxia. Sci. Rep. 7, 9840 (2017).","journal-title":"Sci. Rep."},{"key":"634_CR167","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/ClinicalTrials.gov\/show\/NCT05168774 (2021)."},{"key":"634_CR168","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/ana.24248","volume":"76","author":"M Pandolfo","year":"2014","unstructured":"Pandolfo, M. et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76, 509\u2013521 (2014).","journal-title":"Ann. Neurol."},{"key":"634_CR169","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"S Romano","year":"2015","unstructured":"Romano, S. et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985\u2013991 (2015). This study shows a positive effect of riluzole on SARA score in patients with hereditary ataxia, including some with Friedreich ataxia.","journal-title":"Lancet Neurol."},{"key":"634_CR170","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/21678707.2018.1449638","volume":"6","author":"C Rummey","year":"2018","unstructured":"Rummey, C., Kichula, E. & Lynch, D. R. Clinical trial design for Friedreich ataxia \u2014 where are we now and what do we need? Expert Opin. Orphan Drugs 6, 219\u2013230 (2018).","journal-title":"Expert Opin. Orphan Drugs"},{"key":"634_CR171","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/acn3.51118","volume":"7","author":"C Rummey","year":"2020","unstructured":"Rummey, C. et al. Test-retest reliability of the Friedreich\u2019s ataxia rating scale. Ann. Clin. Transl. Neurol. 7, 1708\u20131712 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"634_CR172","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch, T. et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66, 1717\u20131720 (2006).","journal-title":"Neurology"},{"key":"634_CR173","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/mds.22660","volume":"24","author":"K Burk","year":"2009","unstructured":"Burk, K. et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov. Disord. 24, 1779\u20131784 (2009).","journal-title":"Mov. Disord."},{"key":"634_CR174","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.eclinm.2019.11.006","volume":"18","author":"C Rummey","year":"2020","unstructured":"Rummey, C., Farmer, J. M. & Lynch, D. R. Predictors of loss of ambulation in Friedreich\u2019s ataxia. EClinicalMedicine 18, 100213 (2020).","journal-title":"EClinicalMedicine"},{"key":"634_CR175","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/1545968317712469","volume":"31","author":"SC Milne","year":"2017","unstructured":"Milne, S. C., Corben, L. A., Georgiou-Karistianis, N., Delatycki, M. B. & Yiu, E. M. Rehabilitation for individuals with genetic degenerative ataxia: a systematic review. Neurorehabil. Neural Repair 31, 609\u2013622 (2017).","journal-title":"Neurorehabil. Neural Repair"},{"key":"634_CR176","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","volume":"90","author":"TA Zesiewicz","year":"2018","unstructured":"Zesiewicz, T. A. et al. Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 90, 464\u2013471 (2018). An evidence-based guideline on the management of cerebellar ataxia.","journal-title":"Neurology"},{"key":"634_CR177","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/ene.12341","volume":"21","author":"BP van de Warrenburg","year":"2014","unstructured":"van de Warrenburg, B. P. et al. EFNS\/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur. J. Neurol. 21, 552\u2013562 (2014). An evidence-based guideline on the diagnosis and management of chronic ataxias in adults.","journal-title":"Eur. J. Neurol."},{"key":"634_CR178","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg, W. et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum 13, 248\u2013268 (2014).","journal-title":"Cerebellum"},{"key":"634_CR179","doi-asserted-by":"crossref","first-page":"e040230","DOI":"10.1136\/bmjopen-2020-040230","volume":"10","author":"SC Milne","year":"2020","unstructured":"Milne, S. C. et al. Rehabilitation for ataxia study: protocol for a randomised controlled trial of an outpatient and supported home-based physiotherapy programme for people with hereditary cerebellar ataxia. BMJ Open 10, e040230 (2020).","journal-title":"BMJ Open"},{"key":"634_CR180","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/dmcn.13424","volume":"59","author":"NJH van Os","year":"2017","unstructured":"van Os, N. J. H. et al. Ataxia-telangiectasia: recommendations for multidisciplinary treatment. Dev. Med. Child Neurol. 59, 680\u2013689 (2017).","journal-title":"Dev. Med. Child Neurol."},{"key":"634_CR181","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-014-0184-7","volume":"9","author":"LA Corben","year":"2014","unstructured":"Corben, L. A. et al. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J. Rare Dis. 9, 184 (2014).","journal-title":"Orphanet J. Rare Dis."},{"key":"634_CR182","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s40478-021-01201-x","volume":"9","author":"SR Chintalaphani","year":"2021","unstructured":"Chintalaphani, S. R., Pineda, S. S., Deveson, I. W. & Kumar, K. R. An update on the neurological short tandem repeat expansion disorders and the emergence of long-read sequencing diagnostics. Acta Neuropathol. Commun. 9, 98 (2021).","journal-title":"Acta Neuropathol. Commun."},{"key":"634_CR183","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1971400915621324","volume":"29","author":"AI Henao","year":"2016","unstructured":"Henao, A. I. et al. Characteristic brain MRI findings in ataxia-neuropathy spectrum related to POLG mutation. Neuroradiol. J. 29, 46\u201348 (2016).","journal-title":"Neuroradiol. J."},{"key":"634_CR184","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1093\/brain\/awp045","volume":"132","author":"T Lonnqvist","year":"2009","unstructured":"Lonnqvist, T., Paetau, A., Valanne, L. & Pihko, H. Recessive twinkle mutations cause severe epileptic encephalopathy. Brain 132, 1553\u20131562 (2009).","journal-title":"Brain"},{"key":"634_CR185","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/hmg\/dds473","volume":"22","author":"R Szklarczyk","year":"2013","unstructured":"Szklarczyk, R. et al. A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia. Hum. Mol. Genet. 22, 656\u2013667 (2013).","journal-title":"Hum. Mol. Genet."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00634-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00634-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T07:01:00Z","timestamp":1700377260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-022-00634-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":185,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["634"],"URL":"https:\/\/doi.org\/10.1038\/s41582-022-00634-9","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"17 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.P. has received grants and personal fees from Biomarin, Minoryx and Voyager Therapeutics, and has received, grants from the European Commission \u2014 7th Framework Programme, Fonds National de la Recherche Scientifique (Belgium) and the Friedreich\u2019s Ataxia Research Alliance, and personal fees from Apopharma, Exicure, Design Therapeutics, Aavanti Bio, and UCB. He has a patent for methods to diagnose Friedreich ataxia (WO1997032996A1), royalties for which have been paid by Athena Diagnostics. None of these disclosures represent a conflict of interest that may be perceived as biasing the content of this manuscript. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}